Korkmaz Hakan, Tabur Suzan, Ozkaya Mesut, Oguz Elif, Elboga Umut, Aksoy Nurten, Akarsu Ersin
a Edirne State Hospital, Endocrinology and Metabolic Disease , 22030 , Turkey.
b Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology , Gaziantep University , 27100 Sahinbey , Turkey.
Redox Rep. 2016 Sep;21(5):227-31. doi: 10.1080/13510002.2015.1107310. Epub 2016 Jan 21.
The aim of this study was to evaluate serum paraoxonase-1 (PON1) activity and its association with oxidative stress in autoimmune thyroid disease (AITD).
A total of 50 patients with AITD, including 25 with Hashimoto's thyroiditis and 25 with Graves' disease were enrolled. The control group comprised 27 healthy subjects. Blood samples were obtained in the euthyroid period and 3 months after initiation of medical treatment. Serum samples from patients with AITD and the healthy control group were analyzed for basal PON1, salt-stimulated PON1, and arylesterase (ARE) activities, along with lipid hydroperoxide (LOOH) and total free sulfhydryl (-SH) levels.
Serum PON1 activities and -SH levels were significantly lower (P < 0.001, for each), whereas LOOH levels were significantly higher (P < 0.001, for each) in patients with AITD, compared to the control group. We observed no significant differences in ARE levels between the patient and healthy control groups (P > 0.05). PON1 activity was positively correlated with -SH (r = 0.522, P < 0.001) and negatively correlated with LOOH (r = -0.487, P < 0.001). PON1 phenotype distribution of the subjects was not significantly different among the three groups (P = 0.961).
Serum PON1 activity is decreased in patients with AITD, and correlated positively with -SH, a well-known antioxidant, and negatively with LOOH, an index of lipid oxidation.
本研究旨在评估自身免疫性甲状腺疾病(AITD)患者血清对氧磷酶-1(PON1)活性及其与氧化应激的关系。
共纳入50例AITD患者,其中25例为桥本甲状腺炎患者,25例为格雷夫斯病患者。对照组包括27名健康受试者。在甲状腺功能正常期及开始药物治疗3个月后采集血样。对AITD患者和健康对照组的血清样本进行基础PON1、盐刺激PON1和芳基酯酶(ARE)活性分析,同时检测脂质过氧化氢(LOOH)和总游离巯基(-SH)水平。
与对照组相比,AITD患者血清PON1活性和-SH水平显著降低(均P<0.001),而LOOH水平显著升高(均P<0.001)。患者组和健康对照组之间的ARE水平无显著差异(P>0.05)。PON1活性与-SH呈正相关(r=0.522,P<0.001),与LOOH呈负相关(r=-0.487,P<0.001)。三组受试者的PON1表型分布无显著差异(P=0.961)。
AITD患者血清PON1活性降低,与著名抗氧化剂-SH呈正相关,与脂质氧化指标LOOH呈负相关。